Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 2180508, 7 pages
https://doi.org/10.1155/2017/2180508
Review Article

Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies

Department of Internal Medicine IV–Nephrology and Hypertension, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria

Correspondence should be addressed to Michael Rudnicki; ta.ca.dem-i@ikcindur.leahcim

Received 3 March 2017; Accepted 20 April 2017; Published 9 May 2017

Academic Editor: Björn Meijers

Copyright © 2017 Michael Rudnicki. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. T. Cook and M. C. Pickering, “Histopathology of MPGN and C3 glomerulopathies,” Nature Reviews Nephrology, vol. 11, no. 1, pp. 14–22, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Levy, M.-C. Gubler, M. Sich, A. Beziau, and R. Habib, “Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (Type I MPGN),” Clinical Immunology and Immunopathology, vol. 10, no. 4, pp. 477–492, 1978. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Habib, M. C. Gubler, C. Loirat, H. B. Mäiz, and M. Levy, “Dense deposit disease: a variant of membranoproliferative glomerulonephritis,” Kidney International, vol. 7, no. 4, pp. 204–215, 1975. View at Publisher · View at Google Scholar · View at Scopus
  4. P. M. Burkholder, A. Marchand, and R. P. Krueger, “Mixed membranous and proliferative glomerulonephritis. A correlative light, immunofluorescence, and electron microscopic study.,” Laboratory Investigation, vol. 23, no. 5, pp. 459–479, 1970. View at Google Scholar · View at Scopus
  5. S. Sethi and F. C. Fervenza, “Membranoproliferative Glomerulonephritis - A New Look at an Old Entity,” New England Journal of Medicine, vol. 366, no. 12, pp. 1119–1131, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. S. H. Nasr, A. M. Valeri, G. B. Appel et al., “Dense deposit disease: Clinicopathologic study of 32 pediatric and adult patients,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 1, pp. 22–32, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Fakhouri, V. Frémeaux-Bacchi, L.-H. Noël, H. T. Cook, and M. C. Pickering, “C3 glomerulopathy: a new classification,” Nature Reviews Nephrology, vol. 6, no. 8, pp. 494–499, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Zhang, N. C. Meyer, K. Wang et al., “Causes of alternative pathway dysregulation in dense deposit disease,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 2, pp. 265–274, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. Q. Chen, D. Müller, B. Rudolph et al., “Combined C3b and factor B autoantibodies and MPGN type II,” New England Journal of Medicine, vol. 365, no. 24, pp. 2340–2342, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. Q. Chen, M. Wiesener, H. U. Eberhardt et al., “Complement factor H-related hybrid protein deregulates complement in dense deposit disease,” Journal of Clinical Investigation, vol. 124, no. 1, pp. 145–155, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. J. S. Cameron, D. R. Turner, J. Heaton et al., “Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis,” The American Journal of Medicine, vol. 74, no. 2, pp. 175–192, 1983. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. Little, P. Dupont, E. Campbell, A. Dorman, and J. J. Walshe, “Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk,” Kidney International, vol. 69, no. 3, pp. 504–511, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. U. Elewa, A. M. Sandri, W. R. Kim, and F. C. Fervenza, “Treatment of hepatitis B virus-associated nephropathy,” Nephron - Clinical Practice, vol. 119, no. 1, pp. c41–c49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Neugarten and D. S. Baldwin, “Glomerulonephritis in bacterial endocarditis,” The American Journal of Medicine, vol. 77, no. 2, pp. 297–304, 1984. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Bartel, N. Obermüller, M. J. Rummel, H. Geiger, and I. A. Hauser, “Remission of a B cell CLL-associated membranoproliferative glomerulonephritis Type I with rituximab and bendamustine,” Clinical Nephrology, vol. 69, no. 4, pp. 285–289, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Bourke, W. G. Campbell Jr., M. Piper, and I. J. Check, “Hypocomplementemic proliferative glomerulonephritis with C3 nephritic-factor-like activity in multiple myeloma,” Nephron, vol. 52, no. 3, pp. 231–237, 1989. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Leung, F. Bridoux, C. A. Hutchison et al., “Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant,” Blood, vol. 120, no. 22, pp. 4292–4295, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Sethi, L. Zand, N. Leung et al., “Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 5, pp. 770–782, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Fabrizi, E. Plaisier, D. Saadoun, P. Martin, P. Messa, and P. Cacoub, “Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease,” The American Journal of Kidney Diseases, vol. 61, no. 4, pp. 623–637, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. G. D'Amico and F. Ferrario, “Mesangiocapillary glomerulonephritis,” Journal of the American Society of Nephrology, vol. 2, supplement 10, pp. S159–S166, 1992. View at Google Scholar
  21. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group, “KDIGO clinical practice guideline for glomerulonephritis,” Kidney International Supplements, vol. 2, supplement 2, pp. 139–274, 2012. View at Publisher · View at Google Scholar
  22. P. Tarshish, J. Bernstein, J. N. Tobin, and C. M. Edelmann Jr., “Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone -a report of The International Study of Kidney Disease in Children,” Pediatric Nephrology, vol. 6, no. 2, pp. 123–130, 1992. View at Publisher · View at Google Scholar · View at Scopus
  23. D. C. Cattran, C. J. Cardella, J. M. Roscoe et al., “Results of a controlled drug trial in membranoproliferative glomerulonephritis,” Kidney International, vol. 27, no. 2, pp. 436–441, 1985. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Faedda, A. Satta, F. Tanda, M. Pirisi, and E. Bartoli, “Immunosuppressive treatment of membranoproliferative glomerulonephritis,” Nephron, vol. 67, no. 1, pp. 59–65, 1994. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Jones, M. Juszczak, E. Kingdon, M. Harber, P. Sweny, and A. Burns, “Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids,” Nephrology Dialysis Transplantation, vol. 19, no. 12, pp. 3160–3164, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Bagheri, E. Nemati, K. Rahbar, A. Nobakht, B. Einollahi, and S. Taheri, “Cyclosporine in the treatment of membranoproliferative glomerulonephritis,” Archives of Iranian Medicine, vol. 11, no. 1, pp. 26–29, 2008. View at Google Scholar · View at Scopus
  27. M. Haddad, K. Lau, and L. Butani, “Remission of membranoproliferative glomerulonephritis type I with the use of tacrolimus,” Pediatric Nephrology, vol. 22, no. 10, pp. 1787–1791, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. T. D. Barbour, M. M. Ruseva, and M. C. Pickering, “Update on C3 glomerulopathy,” Nephrology Dialysis Transplantation, vol. 31, no. 5, pp. 717–725, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. J. C. W. Edwards and G. Cambridge, “B-cell targeting in rheumatoid arthritis and other autoimmune diseases,” Nature Reviews Immunology, vol. 6, no. 5, pp. 394–403, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Fornoni, J. Sageshima, C. Wei et al., “Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis,” Science Translational Medicine, vol. 3, no. 85, Article ID 85ra46, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Vilayur, P. Trevillian, and M. Walsh, “Monoclonal gammopathy and glomerulopathy associated with chronic lymphocytic leukemia,” Nature Clinical Practice Nephrology, vol. 5, no. 1, pp. 54–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Bhat, S. Weiss, G. B. Appel, and J. Radhakrishnan, “Rituximab Treatment of Dysproteinemias Affecting the Kidney: A Review of Three Cases,” American Journal of Kidney Diseases, vol. 50, no. 4, pp. 641–644, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Zaidan, B. Terrier, A. Pozdzik et al., “Spectrum and prognosis of noninfectious renal mixed cryoglobulinemic gn,” Journal of the American Society of Nephrology, vol. 27, no. 4, pp. 1213–1224, 2016. View at Publisher · View at Google Scholar
  34. M. Pietrogrande, S. de Vita, A. L. Zignego et al., “Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients,” Autoimmunity Reviews, vol. 10, no. 8, pp. 444–454, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Dammacco and D. Sansonno, “Therapy for hepatitis C virus-related cryoglobulinemic vasculitis,” New England Journal of Medicine, vol. 369, no. 11, pp. 1035–1045, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. J. J. Dillon, M. Hladunewich, W. E. Haley, H. N. Reich, D. C. Cattran, and F. C. Fervenza, “Rituximab therapy for type I membranoproliferative glomerulonephritis,” Clinical Nephrology, vol. 77, no. 4, pp. 290–295, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Sugiura, T. Takei, M. Itabashi et al., “Effect of single-dose rituximab on primary glomerular diseases,” Nephron—Clinical Practice, vol. 117, no. 2, pp. c98–c105, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. W. Y. Kong, R. Swaminathan, and A. Irish, “Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature,” International Urology and Nephrology, vol. 45, no. 3, pp. 795–802, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. R. J. H. Smith, J. Alexander, P. N. Barlow et al., “New approaches to the treatment of dense deposit disease,” Journal of the American Society of Nephrology, vol. 18, no. 9, pp. 2447–2456, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Giaime, L. Daniel, and S. Burtey, “Remission of C3 glomerulopathy with rituximab as only immunosuppressive therapy,” Clinical Nephrology, vol. 83, no. 1, pp. 57–60, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Daina, M. Noris, and G. Remuzzi, “Eculizumab in a patient with dense-deposit disease,” New England Journal of Medicine, vol. 366, no. 12, pp. 1161–1163, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Rousset-Rouvière, M. Cailliez, F. Garaix, D. Bruno, D. Laurent, and M. Tsimaratos, “Rituximab fails where eculizumab restores renal function in C3nef-related DDD,” Pediatric Nephrology, vol. 29, no. 6, pp. 1107–1111, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Payette, N. Patey, M.-A. Dragon-Durey, V. Frémeaux-Bacchi, F. Le Deist, and A.-L. Lapeyraque, “A case of C3 glomerulonephritis successfully treated with eculizumab,” Pediatric Nephrology, vol. 30, no. 6, pp. 1033–1037, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Riedl, P. Thorner, and C. Licht, “C3 glomerulopathy,” Pediatric Nephrology, vol. 32, no. 1, pp. 43–57, 2016. View at Publisher · View at Google Scholar · View at Scopus
  45. A. S. Bomback, R. J. Smith, G. R. Barile et al., “Eculizumab for dense deposit disease and C3 glomerulonephritis,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 5, pp. 748–756, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. M. J. S. Oosterveld, M. R. Garrelfs, B. Hoppe et al., “Eculizumab in pediatric dense deposit disease,” Clinical Journal of the American Society of Nephrology, vol. 10, no. 10, pp. 1773–1782, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Zand, E. C. Lorenz, F. G. Cosio et al., “Clinical findings, pathology, and outcomes of C3GN after kidney transplantation,” Journal of the American Society of Nephrology, vol. 25, no. 5, pp. 1110–1117, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. E. C. Lorenz, S. Sethi, N. Leung, A. Dispenzieri, F. C. Fervenza, and F. G. Cosio, “Recurrent membranoproliferative glomerulonephritis after kidney transplantation,” Kidney International, vol. 77, no. 8, pp. 721–728, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. E. Schrezenmeier, K. Wu, F. Halleck et al., “Successful recovery of acute renal transplant failure in recurrent hepatitis c virus-associated membranoproliferative glomerulonephritis,” American Journal of Transplantation, vol. 17, no. 3, pp. 819–823, 2017. View at Publisher · View at Google Scholar
  50. Y.-H. H. Lien and K. Scott, “Long-term cyclophosphamide treatment for recurrent type I membranoproliferative glomerulonephritis after transplantation,” American Journal of Kidney Diseases, vol. 35, no. 3, pp. 539–543, 2000. View at Publisher · View at Google Scholar · View at Scopus
  51. K. A. Muczynski, “Plasmapheresis maintained renal function in an allograft with recurrent membranoprolifevative glomerulonephritis type I,” American Journal of Nephrology, vol. 15, no. 5, pp. 446–449, 1995. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Farooqui, K. Alsaad, N. Aloudah, and H. Alhamdan, “Treatment-resistant recurrent membranoproliferative glomerulonephritis in renal allograft responding to rituximab: Case report,” Transplantation Proceedings, vol. 47, no. 3, pp. 823–826, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. M. J. Pérez-Sáez, K. Toledo, M. D. Navarro et al., “Recurrent membranoproliferative glomerulonephritis after second renal graft treated with plasmapheresis and rituximab,” Transplantation Proceedings, vol. 43, no. 10, pp. 4005–4009, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. O. Bestard, J. M. Cruzado, G. Ercilla et al., “Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft,” Nephrology Dialysis Transplantation, vol. 21, no. 8, pp. 2320–2324, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. J. A. McCaughan, D. M. O'Rourke, and A. E. Courtney, “Recurrent dense deposit disease after renal transplantation: An emerging role for complementary therapies,” American Journal of Transplantation, vol. 12, no. 4, pp. 1046–1051, 2012. View at Publisher · View at Google Scholar · View at Scopus